Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
relacorilant + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Corcept Therapeutics
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Relacorilant + nab-paclitaxel is a combination therapy under investigation for the treatment of platinum-resistant ovarian cancer and other solid tumors. Relacorilant is a selective glucocorticoid receptor antagonist that inhibits glucocorticoid receptor (GR) signaling, which can mediate resistance to chemotherapy. Nab-paclitaxel (nanoparticle albumin-bound paclitaxel, marketed as Abraxane) is a microtubule inhibitor used in various cancers. The combination aims to enhance the efficacy of chemotherapy by blocking GR-mediated resistance pathways, thereby improving progression-free survival and overall survival compared to nab-paclitaxel alone. Corcept Therapeutics developed relacorilant and sponsors clinical trials evaluating this regimen[1][3][5][6][7].
- Other names
- relacorilant + Abraxane
02
Targets
GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on relacorilant + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on relacorilant + nab-paclitaxel.